The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
Molecular diagnosis of USB1B due to MYO7A mutation
Willingness to adhere to protocol per informed consent
Unwillingness to meet the requirements of the study
Participation in a clinical study with an Investigation Product in the past 6 months
Previous participation in another Gene Therapy trial
Any condition that would preclude subretinal surgery